40 Manning Road
460 articles with Bruker Corporation
Bruker Corporation announced it will report second quarter 2021 financial results on Monday, August 2, 2021, after the market closes.
Novel 4D-Metabolomics and 4D-Lipidomics Workflows, Libraries and ML-based CCS Prediction Tools to Transform Metabolomics and Lipidomics
Bruker Corporation today announced the launch of a new VIP-HESI ion source to increase sensitivity dramatically, and new integrated software tools to increase confidence in 4D-Metabolomics and 4D-Lipidomics workflows.
At its 2021 Virtual Investor Day today, Bruker Corporation (Nasdaq: BRKR) will discuss the Company’s strategy and Project Accelerate 2.0 initiatives, including the Company’s potential high-growth opportunities in the areas of proteomics and spatial biology.
Bruker Corporation will host a Virtual Investor Day on June 17th, 2021, starting at 10:00 AM Eastern Daylight Time.
Bruker Launches CE-IVD Quantitative Coronavirus Mid-Plex PCR Assay with Mutation Detection for Routine Variant Differentiation
Bruker Corporation announced the launch of the FluoroType SARS-CoV-2 varID Q assay – a quantitative LiquidArray® mid-plex PCR panel.
Bruker Launches timsTOF trueSCP for Unbiased Single Cell 4D-Proteomics and Next-gen timsTOF Pro 2 with Unprecedented Proteomic Depth
Unique timsTOF trueSCP revolutionizes quantitative single cell biology research with unbiased, deep single-cell 4D-Proteomics™ to complement scRNA-seq; breakthrough paper by Mann et al. identifies and quantifies >1,400 proteins in single cells
Bruker’s Molecular Phenomics Research Tools Enable New Insights into ‘Long COVID’ and Post-Acute Metabolic Abnormalities
Australian National Phenome Centre Integrates Quantitative NMR and MS Assay Platform for Risk Assessment and Longitudinal Monitoring of Post-Acute COVID-19 Syndrome (PACS)
Bruker Announces New Two-Year Share Repurchase Authorization of up to $500 Million; Board also Declares Quarterly Dividend
Bruker Corporation (Nasdaq: BRKR) today announced that on May 12, 2021, its Board of Directors approved a new share repurchase authorization for the purchase of up to $500 million of the Company’s common stock over a two-year period commencing on May 13, 2021.
International Organization of Vine and Wine (OIV) Officially Incorporates NMR Method in Compendium of International Methods of Analysis of Wines and Musts
Nuclear magnetic resonance spectroscopy has been incorporated by the intergovernmental and International Organization of Vine and Wine in its compendium of International Methods of Analysis of Wines and Musts, for the quantification of six key parameters in wine – glucose, malic acid, acetic acid, fumaric acid, shikimic acid and sorbic acid.
Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the following virtual conferences: BofA Securities 2021 Health Care Conference Tuesday, May 11, 2021, at 11:00 a.m. Eastern Time Frank Laukien, Chairman, President and Chief Executive Officer Mark Munch, President, Bruker Nano Group UBS Global Healthcare Virtual Conference Monday, May 24, 2021, at 9:00 a.m. Eastern Time Fran
Q1 2021 revenue growth of 30.8% year-over-year, organic revenue growth of 23.8% Q1 2021 GAAP EPS of $0.37; non-GAAP EPS of $0.44, compared to $0.14 in Q1 2020 Raising fiscal year 2021 outlook on strong demand for the Company’s high-performance life science tools, scientific instruments and diagnostic solutions
Bruker Corporation announced preliminary revenue for the first quarter ended March 31, 2021 in a range of $549 - $554 million, representing reported revenue growth of approximately 30% to 31%, compared to the first quarter of 2020.
Bruker Makes Routine Magnetic Resonance Spectroscopy More Broadly Accessible for Chemical Analysis Outside Central Labs
At ENC 2021, Bruker Showcases Enhanced Benchtop Fourier 80™ FT-NMR, Affordable AvanceCore™ 400 NMR, and Versatile Benchtop Magnettech™ ESR 5000
Bruker Corporation (Nasdaq: BRKR), a leading supplier of single-plane illumination microscopy (SPIM) technology for research on live cells and cleared biological samples, today announced that two Luxendo MuVi™ and LCS SPIM™ light-sheet microscopes have been installed by Memorial Sloan Kettering Cancer Center (MSK).
Bruker Announces New Results in Deep, Unbiased Plasma Proteomics, PaSER 1.1 Software and New Cross-linking Consumables at US HUPO 2021
Roman Fischer of Oxford University demonstrates high-throughput 4D proteomics on non-depleted, untreated plasma identifying >350 protein groups with short 10-20 minute methods, enabling high throughput, robust biomarker discovery OmicEra Diagnostics reports running 720 undepleted serum samples from 31 COVID-19 patients over just 12 days on a single timsTOF Pro system at a rate of 60 samples/day
New Nature Communications Publication by Mann & Theis Groups Harnesses the Benefits of Large-scale Peptide Collisional Cross Section (CCS) Measurements and Deep Learning for 4D Proteomics
Measured more than a million collision cross sections (CCS) from whole-proteome digests of five organisms with trapped ion mobility spectrometry (TIMS) and parallel accumulation-serial fragmentation (PASEF) on several timsTOF Pro systems
Bruker Corporation announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.04 per share on the Company’s common stock.
Feb. 16, 2021 12:00 UTC Q4 2020 revenues up 4.6% year-over- Q4 2020 GAAP EPS of $0.45; non-GAAP EPS of $0.58 Expanded Project Accelerate 2.0 in proteomics, spatial biology and molecular diagnostics Strong revenue growth, Non-GAAP margin expansion and EPS growth expected in FY 2021
Bruker Corporation (Nasdaq: BRKR) today announced it will report fourth quarter and fiscal year 2020 financial results on Tuesday, February 16, 2021, before the market opens.
Collaboration to evaluate the clinical utility of the high throughput bead assisted mass spectrometry (BAMS™) test for SARS-CoV-2 infection developed with Adeptrix